NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £250,000,000 |
|---|---|
| Status | planned |
| Category (CPV) | 33141530 |
| Region | Scotland, Wales, Northern Ireland |
| Contract start | 1 Jul 2024 |
| Contract end | 30 Jun 2026 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-1c50622d-4400-421e-8893-3dc6eba40a12 |
description
Bleeding Disorders including Haemophilia B
The purpose of this 'future opportunity' notice is to indicate that a live 'opportunity' may be published at a future date. However, any existing 'live' framework agreement may be subject to an extension up to the maximum extension period allowed.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 5 Jul 2022 | Planning (planning) | · | b5f6a6d1-3e3f-459c-be9f-932bac7dd3b0-552104 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin · £526,598,540 · 3 Feb 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
- NHS National Framework Agreement for the supply of products for the management of Herediatary Angioedema · £74,500,000 · 3 Feb 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Purchase of Diathermy · Leeds Teaching Hospitals NHS Trust · £48,000
- Provision of R-Phycoerythrin F(ab)2-specific IgG antibody · Public Health England · £130,000
- NHS Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B · NHS England · £192,000,000
- Provision of R-Phycoerythrin F(ab)2-specific IgG antibody · Public Health England · £44,601
- National Framework Agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders · NHS England · £302,000,000
- HOME DELIVERY OF RECOMBINANT COAGULATION FACTORS FOR HAEMOPHILIA PATIENTS · University Hospitals of North Midlands NHS Trust
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.